Clinical Trials

Phase EARLY_PHASE1 Recruiting

Colorectal Neoplasms

NCT04741997 2026-03-02

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

50 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Melanoma

NCT07318389 2026-02-27

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

100 enrolled

Phase EARLY_PHASE1 Active not recruiting

Colorectal Neoplasms

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

14 enrolled

Phase 2/3 Active not recruiting

Melanoma, Skin Neoplasms

NCT05710406 2026-01-26

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

1 enrolled

Colonic Neoplasms

NCT06578559 2026-01-05

BRICKET

16 enrolled

Colorectal Neoplasms

NCT03803553 2025-12-23

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Phase 3 Recruiting

400 enrolled

Colonic Neoplasms

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

52 enrolled

Brain Neoplasms, Melanoma

NCT06194929 2025-12-03

DETERMINE

Phase 1/2 Recruiting

33 enrolled

Phase 1/2 Active not recruiting

Brain Neoplasms, Melanoma

NCT04017650 2025-11-20

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

38 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

NCT04061980 2025-11-19

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

24 enrolled

Head & Neck

Thyroid Neoplasms

NCT04526782 2025-11-18

ENCO-BRAF

119 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05576896 2025-10-20

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

43 enrolled

Colorectal Neoplasms

NCT06887088 2025-10-01

ENCEFALO

33 enrolled

Phase 2 Not yet recruiting

Brain Neoplasms, Melanoma

NCT07178717 2025-09-17

REFISH

25 enrolled

Colonic Neoplasms

NCT05706779 2025-09-02

NEORAF

30 enrolled

Phase 4 Not yet recruiting

Colorectal Neoplasms

NCT07092410 2025-07-29

SuRage-EB

101 enrolled

Melanoma

NCT03898908 2025-05-21

EBRAIN-MEL

48 enrolled 24 charts

Brain Neoplasms, Melanoma, Neoplasm Metastasis

NCT05615818 2025-04-23

SAFIR-ABC10

Phase 3 Recruiting

800 enrolled

Biliary Tract Neoplasms

NCT06640166 2025-02-12

ECLYPse

25 enrolled

Colonic Neoplasms, Colorectal Neoplasms

NCT06411600 2024-11-08

BRAVE

94 enrolled

Colorectal Neoplasms

NCT03973918 2024-10-31

BRAF

Phase 2 Terminated

5 enrolled 15 charts

CNSSarcoma

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

NCT01894672 2024-07-16

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

7 enrolled 9 charts

Melanoma

NCT02631447 2024-06-07

SECOMBIT

251 enrolled

Melanoma

NCT04074096 2024-06-03

BEPCOME-MB

10 enrolled

Brain Neoplasms, Melanoma

NCT04655157 2024-05-23

QUAD01

Phase 1/2 Terminated

2 enrolled 12 charts

Melanoma

NCT04390243 2024-05-06

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Phase 2 Terminated

6 enrolled 16 charts

Pancreatic Neoplasms

NCT04720768 2024-01-05

CELEBRATE

Phase 1/2 Unknown

78 enrolled

Melanoma, Neoplasm Metastasis

NCT02834364 2023-11-24

GMMG-BIRMA

12 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT03563729 2023-07-13

MEMBRAINS

80 enrolled

Brain Neoplasms, Melanoma

NCT04801966 2023-05-10

TAILOR

Phase NA Terminated

3 enrolled

Tumor-Agnostic

Neoplasms

NCT05725200 2023-02-21

EVIDENT

40 enrolled

Colorectal Neoplasms

NCT05097378 2021-10-28

PREMIUM

Phase 2 Unknown

45 enrolled

Melanoma, Neoplasms

NCT02263898 2020-07-27

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Phase 2 Withdrawn